CHT offers medical gas services to help you achieve your compliance goals. To help you meet these challenges, we offer a free 30-minute discovery call. In section 211.94(e)(1) of the proposed rule, the FDA proposed to ban cryogenic containers and high-pressure cylinders used to ingest industrial gases, subject to limited exceptions for medical purposes. An explanation of the contents of a typical gas cylinder label and a guide to the color coding system used on gas cylinders. Describes the requirement to keep medical gas cylinders clean and covers the methods used to clean the outer surface or return a cylinder in protective packaging. It does not deal with the internal state of a gas tank or the quality of the gas it contains. Description of Respondents: Individuals and businesses, including small businesses and manufacturers, involved in the processing, manufacture, transportation, handling and management of designated medical gases. The FDA`s database of facilities that produce medical gases includes about 2,500 such facilities. The Food and Drug Administration (FDA) is changing its Good Manufacturing Practices (GMP) and current regulations for medical gas labelling. The FDA requires that portable cryogenic medical gas containers that are not manufactured with permanent gas outlet connections have gas-specific outlet connectors that cannot be easily removed or replaced except by the manufacturer.
The FDA also requires portable cryogenic medical gas containers and high-pressure medical gas cylinders to meet certain labeling, naming, and color requirements. These requirements are designed to increase the likelihood that the contents of medical gas containers will be accurately identified and reduce the likelihood that the wrong gas will be connected to a gas Start Printed Page 81686Supplement system or container. The FDA is also revising an existing regulation that conditionally exempts certain medical gases from certain otherwise applicable labeling requirements to add oxygen and nitrogen to the list of gases subject to the exemption and to remove cyclopropane and ethylene from the list. This final rule includes requirements for the collection of information that are reviewed by the OMB under the Paperwork Reduction Act of 1995 (PRA) (44 U.S.C. 3501-3520). The title, description and description of the information collection provisions are presented in this section with an estimate of the disclosure burden and records by third parties. The estimate includes the time required to review instructions, search for existing data sources, collect and manage the required data, and complete and review each collection of information. (Comment 1) Many commentators argue that the FDA`s proposal does not reflect risk-based principles formulated in the past in the context of the recent CGMP policy. These comments indicate that risk-based principles focus regulation on critical areas of greatest public health impact.
These comments therefore indicate that the effects of the FDA`s proposed rule are disproportionate and that beyond the scope of a public health risk associated with medical gases, they are inconsistent with the agency`s risk-based approach to GMP. The notices also argue that the incidents mentioned in the preamble to the proposed rule do not support the number of proposed requirements and that only one requirement of the proposed rule – the requirement for secure connections on portable containers – would have prevented all but one of the deaths mentioned in the preamble. Certain devices, such as medical gas regulators, demand valves and medical gas flow meters associated with the administration of medical gases, are classified as medical devices. Medical devices must be fitted with a corresponding test mark. This can be the UK CA mark or the European CE marking, it is a declaration from the manufacturer that the device complies with the relevant medical device regulations. Any organisation wishing to manufacture medical devices (including medical gases classified as gases for medical devices) must comply with the requirements of the relevant Medical Devices Regulation and be registered with the MHRA. (Response to footnotes 20 and 21) The FDA agrees that the definition of “portable cryogenic medical gas containers,” as commonly used, should be clarified. Therefore, in the final rule, we specify that cryogenic gas containers that are not designed to connect to a medical gas supply system, including tankers, trailers, railway cars and domestic liquid oxygen units, are exempt from the requirement of a gas-specific safe outlet connection.
Paragraph 201.328(a)(1)(v) also provides that a portable cryocy cylinder may be dyed in the colours referred to in paragraph 201.328(c) only if the gas or gases in the container correspond to that colour or colours. Alternatively, the container may be in a light-reflecting color such as white (or another color that is not an FDA-designated gas color) or simply not colored at all. Based on discussions with subject matter experts, we believe that few or no cryogenic containers need to be recolored due to this requirement, and therefore believe that there is no third-party disclosure burden associated with this requirement. As a result, the FDA has proposed certain regulatory requirements to (1) reduce the likelihood of the wrong gas being connected to a gas supply system or gas tank (and in particular reduce the likelihood that a gas other than oxygen will be connected to an oxygen supply system), (2) make the contents of medical gas containers easier and more accurately identifiable, and (3) reduce the risk of contamination of medical gases. In addition, the FDA has proposed to include and exclude medical air, oxygen, and nitrogen from the list of gases that are conditionally exempt from certain labeling requirements, as described in § 201.161 (21 CFR 201.161). The FDA has requested written comments on the proposed rule. The FDA also looked at the economic impact of the rule, as required by the Regulatory Flexibility Act.